CEFTRIAXONE FOR INJECTION 100 G
CEFTRIAXONE (CEFTRIAXONE SODIUM) : 100 G · DIN 02409968 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is CEFTRIAXONE FOR INJECTION?
CEFTRIAXONE FOR INJECTION 100 G contains CEFTRIAXONE (CEFTRIAXONE SODIUM) : 100 G. It is listed in the Health Canada Drug Product Database under DIN 02409968, held by FRESENIUS KABI CANADA LTD, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 09-Oct-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CEFTRIAXONE FOR INJECTION used for?
Ceftriaxone for Injection is indicated for the treatment of various bacterial infections including lower respiratory tract infections, urinary tract infections, bacterial septicemia, skin and skin structure infections, bone and joint infections, intra-abdominal infections, meningitis (excluding that caused by L. monocytogenes), and uncomplicated gonorrhea. It is also indicated for preoperative prophylaxis in certain surgeries.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02409968 |
|---|---|
| Brand name | CEFTRIAXONE FOR INJECTION |
| Generic / active ingredient | CEFTRIAXONE (CEFTRIAXONE SODIUM) : 100 G |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 100 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01DD04 CEFTRIAXONE |
| AHFS class | 08:12.06.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Oct-2015 |
| Original market date | 2014-06-05 00:00:00 |
How is it stored and handled?
null
How is it supplied?
• 10 mL or 15 mL vials containing sterile powder ceftriaxone sodium equivalent to 0.5 g of ceftriaxone, packaged in 25 vials per carton or 10 vials per carton, respectively. • 10 mL or 15 mL vials containing sterile powder ceftriaxone sodium equivalent to 1 g of ceftriaxone, packaged in 25 vials per carton or 10 vials per carton, respectively. • 20 mL vials containing sterile powder ceftriaxone sodium equivalent to 2 g of ceftriaxone, packaged in 10 vials per carton. • 100 mL Pharmacy Bulk Package vials containing ceftriaxone sodium equivalent to 10 grams of ceftriaxone packaged individually. • 100 grams SmartPak® “Pharmacy Bulk Package” containing sterile powder ceftriaxone sodium equivalent to 100 grams of ceftriaxone.
Is CEFTRIAXONE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01DD04 CEFTRIAXONE. 13 of 41 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CEFTRIAXONE FOR INJECTION | 1 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02289695 |
| CEFTRIAXONE FOR INJECTION | 2 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02289709 |
| CEFTRIAXONE INJECTION, USP | 1000 MG / 50 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02499711 |
| CEFTRIAXONE INJECTION, USP | 2000 MG / 50 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02499738 |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 1 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02292270 |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 1 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02325616 |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 10 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02325632 |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 10 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02292297 |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 2 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02292289 |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 2 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02325624 |
Who else supplies CEFTRIAXONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFTRIAXONE appears in 7521 registered pack listings across 9 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.